[{"id":"95201ef8-2fab-45a7-9703-ae99f68e157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04388475","created_at":"2021-07-05T17:30:04.951Z","updated_at":"2024-07-02T16:35:11.963Z","phase":"Phase 2","brief_title":"Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT04388475","lead_sponsor":"Oblato, Inc.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • disufenton sodium (OKN-007)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 06/12/2020","start_date":" 06/12/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-04-02"}]